(Q27851566)

English

Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).

scientific article

In more languages

Statements

scholarly article

1 reference

13 November 2016

Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I). (English)

1 reference

13 November 2016

1 reference

based on heuristic

inferred from title

non-small-cell lung carcinoma

1 reference

based on heuristic

inferred from title

author name string

Katsuhiro Masago

1

0 references

Shiro Fujita

2

0 references

Kaoru Irisa

3

0 references

Yung Hak Kim

4

0 references

Masataka Ichikawa

5

0 references

Tadashi Mio

6

0 references

Michiaki Mishima

7

0 references

publication date

November 2010

0 references

Japanese Journal of Clinical Oncology

0 references

40

0 references

11

0 references

1105-9

0 references

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ087

21 January 2018

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ087

21 January 2018

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ087

21 January 2018

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ087

21 January 2018

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ087

21 January 2018

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ087

21 January 2018

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ087

21 January 2018

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ087

21 January 2018

Predictors of the response to gefitinib in refractory non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ087

21 January 2018

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ087

21 January 2018

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ087

21 January 2018

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ087

21 January 2018

Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ087

21 January 2018

Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ087

21 January 2018

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ087

21 January 2018

Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ087

21 January 2018

Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ087

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ087

21 January 2018

Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ087

21 January 2018

Update on epidermal growth factor receptor mutations in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYQ087

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27851566&oldid=1624156326"